Prometheus Biosciences, Inc., (RXDX): Price and Financial Metrics
RXDX Price/Volume Stats
Current price | $199.92 | 52-week high | $199.98 |
Prev. close | $199.74 | 52-week low | $23.27 |
Day low | $199.60 | Volume | 1,860,600 |
Day high | $199.98 | Avg. volume | 913,102 |
50-day MA | $184.19 | Dividend yield | N/A |
200-day MA | $109.60 | Market Cap | 9.56B |
RXDX Stock Price Chart Interactive Chart >
Prometheus Biosciences, Inc., (RXDX) Company Bio
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 2016 and is based in San Diego, California.
Latest RXDX News From Around the Web
Below are the latest news stories about PROMETHEUS BIOSCIENCES INC that investors may wish to consider to help them evaluate RXDX as an investment opportunity.
Top Healthcare Stocks for June 2023Top healthcare stocks include Theravance Biopharma for best value, Dr Reddy's Laboratories for fastest growth, and Viking Therapeutics for most momentum. |
Top Small-Cap Stocks for June 2023Biggest movers include Prometheus, TG Therapeutics, and Akero Therapeutics, all more than quadrupling in price in the last year while the Russell 2000 Index stays nearly unchanged. |
3 Innovative Growth Stocks to Buy for Next-Gen ProfitsThese are the innovative growth stocks for future profits and these stocks are poised for multibagger returns. |
Is Bristol Myers Squibb a Top Dividend Stock?Its hefty yield isn't the only reason to consider buying this top pharma stock. |
3 Undervalued Pharma Stocks to Buy for High Total ReturnsThese are the undervalued pharma stocks to buy for high total returns as these companies are poised for steady growth and cash flow upside. |
RXDX Price Returns
1-mo | N/A |
3-mo | N/A |
6-mo | N/A |
1-year | 3.05% |
3-year | 693.65% |
5-year | N/A |
YTD | N/A |
2023 | 0.00% |
2022 | 178.20% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...